Pair page
Mazdutide with Retatrutide
Mechanism-tag overlap and published literature for Mazdutide and Retatrutide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
Mazdutide unique
dual-glp-1-glucagon-receptor-agonist
Shared
incretin-peptide
Retatrutide unique
triple-receptor-agonist
Quick facts
Mazdutide
RouteSubQ once weekly
Half-lifeWeekly dosing compatible
FDA statusNot approved
WADANot listed
Retatrutide
RouteSubQ, once weekly
Half-life~6 days
FDA statusInvestigational (Phase 3)
WADANot specifically named
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | Mazdutide | Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al; GLORY-1 Investigators. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225. PMID: 40421736. DOI: 10.1056/NEJMoa2411528. (Pivotal GLORY-1 Phase 3 publication, May 2025.) PMID 40421736 | human trial, Phase 3 |
| 2025 | Mazdutide | Ji L, Qian L, et al; DREAMS-1 Investigators. Mazdutide in Chinese adults with untreated type 2 diabetes: DREAMS-1 Phase 3 trial. Nature. 2025. (Accelerated Article Preview publication, late 2025; part of back-to-back Nature release.) | human trial, Phase 3 |
| 2025 | Mazdutide | Ji L, et al; DREAMS-2 Investigators. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes inadequately controlled on oral medication: DREAMS-2 Phase 3 trial. Nature. 2025. (Back-to-back with DREAMS-1.) | human trial, Phase 3 |
| 2025 | Mazdutide | Innovent Biologics press release. Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature. November 2025. | human trial, Phase 3 |
| 2025 | Mazdutide | BioSpace press release. Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3). May 15, 2025. | human trial, Phase 3 |
| 2018 | Mazdutide | Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391(10… PMID 29945726 | human trial, Phase 2 |
| 2022 | Mazdutide | Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinical… PMID 36337827 | human trial, Phase 1 |
| 2022 | Mazdutide | Jiang H, Pang S, Zhang Y, Yu T, Liu M, Deng H, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022;13(1):3613. PMID: 35750890. (Phase 1b / dose… PMID 35750890 | human trial, Phase 1 |
| 2025 | Mazdutide | Innovent Biologics press release. Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes. September 19, 2025. | human study |
| 2017 | Mazdutide | Sánchez-Garrido MA, Brandt SJ, Clemmensen C, Müller TD, DiMarchi RD, Tschöp MH. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017;60(10):1851-1861. PMID: 28733905. (Class review.) PMID 28733905 | human study |
| 2009 | Mazdutide | Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10):2258-2266. PMID: 19602537. (Preclinical proof-of-concept for the dual-agonist class.) PMID 19602537 | preclinical, in vivo |
| 2018 | Mazdutide | Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641. (GLP-1 mechanism framework.) PMID 29617641 | research article |
| 2025 | Retatrutide | Rosenstock J, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. PMID: 40609566. PMID 40609566 | human trial, Phase 2 |
| 2024 | Retatrutide | Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID: 38858523. PMID 38858523 | human trial, Phase 2 |
| 2023 | Retatrutide | Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972. PMID 37366315 | human trial, Phase 2 |
| 2023 | Retatrutide | Rosenstock J, Frías JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544.… PMID 37385280 | human trial, Phase 2 |
| 2025 | Retatrutide | Eli Lilly and Company. Topline TRIUMPH-4 readout — retatrutide in adults with obesity and knee osteoarthritis. Press release, October 2025. | human trial |
| 2023 | Retatrutide | Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. (Comparator reference.) PMID 37952131 | human trial |
| 2022 | Retatrutide | Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024. (Comparator reference.) PMID 35658024 | human trial |
| 2021 | Retatrutide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. (Comparator reference.) PMID 33567185 | human trial |
| — | Retatrutide | Kjeldsen SAS, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. PMID: 41090431. PMID 41090431 | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adult Participants Who Have Obesity or Are Overweight With Weight-Related Medical Problems (TRIUMPH-1). NCT05929066. | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adult Participants With Obesity and Type 2 Diabetes (TRIUMPH-2). NCT05929079. | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight With Osteoarthritis of the Knee (TRIUMPH-4). NCT05931367. | human trial |
Related pair pages
More research context
Frequently asked
Have Mazdutide and Retatrutide been studied together?
No co-administration studies between Mazdutide and Retatrutide are catalogued on Kalios. The pair page lists only the individual published literature for each compound and any shared mechanism tags.
What mechanisms do Mazdutide and Retatrutide share?
Mazdutide and Retatrutide share these mechanism tags on their Kalios profiles: incretin-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Mazdutide and Retatrutide?
Mazdutide: Not approved. Retatrutide: Investigational (Phase 3). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Mazdutide and Retatrutide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Mazdutide profile and the Retatrutide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026